Summary of COVID-19 P2Et studies

1. Urueña et al., Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)

91 patient P2Et late treatment RCT: 24% lower ICU admission (p=0.76) and 23% shorter hospitalization (p=0.12).
RCT 91 hospitalized COVID-19 patients in Colombia showing no significant differences in clinical outcomes with P2Et treatment. P2Et treatment was associated with reduced pro-inflammatory cytokines (G-CSF, IL-5, IL-18) and increased NK cells and other immune populations.
Sep 2022, Frontiers in Medicine, https://www.frontiersin.org/articles/10.3389/fmed.2022.991873/full, https://c19p.org/uruena